$846 Million is the total value of Bellevue Group AG's 132 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Q | New | QUINTILES IMS HOLDING INC | $5,954,000 | – | 66,520 | +100.0% | 0.70% | – |
| CBPO | New | CHINA BIOLOGIC PRODS INC | $4,100,000 | – | 36,250 | +100.0% | 0.48% | – |
| IPXL | New | IMPAX LABORATORIES INC | $2,818,000 | – | 175,000 | +100.0% | 0.33% | – |
| QGEN | New | QIAGEN NV | $2,664,000 | – | 79,444 | +100.0% | 0.32% | – |
| BIB | New | PROSHARES TR | $1,015,000 | – | 19,000 | +100.0% | 0.12% | – |
| IRTC | New | IRHYTHM TECHNOLOGIES INC | $999,000 | – | 23,500 | +100.0% | 0.12% | – |
| HMSY | New | HMS HLDGS CORP | $925,000 | – | 50,000 | +100.0% | 0.11% | – |
| EVHC | New | ENVISION HEALTHCARE CORP | $816,000 | – | 13,026 | +100.0% | 0.10% | – |
| COTV | New | COTIVITI HLDGS INC | $780,000 | – | 21,000 | +100.0% | 0.09% | – |
| HCM | New | HUTCHISON CHINA MEDTECH LTDsponsored adr | $682,000 | – | 29,242 | +100.0% | 0.08% | – |
| TRHC | New | TABULA RASA HEALTHCARE INC | $555,000 | – | 36,907 | +100.0% | 0.07% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $497,000 | – | 40,000 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bellevue Asset Management AG #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.